Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor

被引:52
作者
McLendon, RE [1 ]
Wikstrand, CJ [1 ]
Matthews, MR [1 ]
Al-Baradei, R [1 ]
Bigner, SH [1 ]
Bigner, DD [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
关键词
epidermal growth factor receptor; glioblastoma; immunotherapy; oligodendroglioma; tumor grade;
D O I
10.1177/002215540004800807
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Epidermal growth factor receptor (EGFR), its variant, EGFRvIII, and tenascin are glioma-associated antigens that are hyperexpressed by neoplastic glial cells relative to normal brain, making them attractive antigenic targets for immunotherapy. Preliminary surveys indicate that oligodendroglial tumors also produce these proteins, although the exact patterns and degrees of reactivity are not known. In this study we examined the immunoreactivity of tenascin among 50 oligodendroglial tumors, including 25 well-differentiated oligodendrogliomas (WDOs) and 12 glioblastomas (GBMs) exhibiting high proportions of oligodendroglia-like cells. We used well-characterized immunoreagents with defined specificities against the target antigens on formalin-fixed, paraffin-embedded archival tissue. The tumors were graded according to WHO guidelines. Immunoreactivity was reported on a 1-3 scale according to staining intensity multiplied by a 1-3 distribution scale distribution within tumor as focal (1), multifocal (2), and diffuse (3) for both the parenchymal and the perivascular components. Although there is considerable overlap in antigen production among the grades of tumor, this study establishes the production of tenascin and wild-type EGFR (but not EGFR vIII) in oligodendroglial neoplasms and supports the concept that antigen production increases with tumor grade.
引用
收藏
页码:1103 / 1110
页数:8
相关论文
共 39 条
  • [1] THE EXTRACELLULAR-MATRIX MOLECULE TENASCIN - EXPRESSION IN THE DEVELOPING CHICK RETINOTECTAL SYSTEM AND SUBSTRATE PROPERTIES FOR RETINAL GANGLION-CELL NEURITES IN-VITRO
    BARTSCH, S
    HUSMANN, K
    SCHACHNER, M
    BARTSCH, U
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 1995, 7 (05) : 907 - 916
  • [2] BARTSCH S, 1992, J NEUROSCI, V12, P736
  • [3] BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251
  • [4] PHASE-I STUDIES OF TREATMENT OF MALIGNANT GLIOMAS AND NEOPLASTIC MENINGITIS WITH I-131 RADIOLABELED MONOCLONAL-ANTIBODIES ANTI-TENASCIN 81C6 AND ANTI-CHONDROITIN PROTEOGLYCAN SULFATE ME1-14 F(AB')(2) - A PRELIMINARY-REPORT
    BIGNER, DD
    BROWN, M
    COLEMAN, RE
    FRIEDMAN, AH
    FRIEDMAN, HS
    MCLENDON, RE
    BIGNER, SH
    ZHAO, XG
    WIKSTRAND, CJ
    PEGRAM, CN
    KERBY, T
    ZALUTSKY, MR
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1995, 24 (01) : 109 - 122
  • [5] Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results
    Bigner, DD
    Brown, MT
    Friedman, AH
    Coleman, RE
    Akabani, G
    Friedman, HS
    Thorstad, WL
    McLendon, RE
    Bigner, SH
    Zhao, XG
    Pegram, CN
    Wikstrand, CJ
    Herndon, JE
    Vick, NA
    Paleologos, N
    Cokgor, I
    Provenzale, JM
    Zalutsky, MR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2202 - 2212
  • [6] Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
    Bigner, SH
    Matthews, MR
    Rasheed, BKA
    Wiltshire, RN
    Friedman, HS
    Friedman, AH
    Stenzel, TT
    Dawes, DM
    McLendon, RE
    Bigner, DD
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) : 375 - 386
  • [7] BLASBERG RG, 1987, CANCER RES, V47, P4432
  • [8] BOURDON MA, 1983, CANCER RES, V43, P2796
  • [9] Broholm H, 1999, CLIN NEUROPATHOL, V18, P176
  • [10] Brown MT, 1996, CLIN CANCER RES, V2, P963